Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OpGen Inc OPGN

Healthcare Biotechnology
OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The Company's... see more

Recent & Breaking News (OTCPK:OPGN)

OpGen Presents Preliminary Acuitas® AMR Gene Panel Data for Detecting Urinary Tract Infections

GlobeNewswire October 7, 2019

OpGen to Present on Guiding Precision Antibiotic Therapy with Rapid Genomics and Informatics at IDWeek 2019

GlobeNewswire September 26, 2019

OpGen Provides update on Curetis Group's R&D Collaboration

GlobeNewswire September 18, 2019

OpGen Reports Second Quarter 2019 Financial Results and Provides Business Update

GlobeNewswire August 7, 2019

OpGen Announces Date of Second Quarter 2019 Financial Results Conference Call

GlobeNewswire July 30, 2019

OpGen's Acuitas® AMR Gene Panel Shows Potential for Reducing Total Time to Targeted Therapy

GlobeNewswire June 27, 2019

OpGen Announces New Data Demonstrating Clinical Utility for Antibiotic Resistant Urinary Tract Infection Patient Management and for Rapid Carbapenem-Resistant Bacteria Outbreak Detection

GlobeNewswire June 13, 2019

OpGen Reports First Quarter 2019 Financial Results and Provides Business Update

GlobeNewswire May 14, 2019

OpGen Completes Initial FDA 510(k) Submission for its Acuitas® AMR Gene Panel Test to Identify Presence of Antibiotic Resistance

GlobeNewswire May 14, 2019

OpGen Announces Date of First Quarter 2019 Financial Results Conference Call

GlobeNewswire May 7, 2019

OpGen Announces Closing of Public Offering of Common Stock

GlobeNewswire March 29, 2019

OpGen Data Predicting Antibiotic Resistance Published in Antimicrobial Agents and Chemotherapy Journal

GlobeNewswire March 28, 2019

OpGen Announces Pricing of a $5.4 Million Public Offering of Common Stock

GlobeNewswire March 26, 2019

OpGen and Merck’s ILÚM Health Solutions to Host Event at VIII International Symposium on Hospital Acquired Infections and Antimicrobial Stewardship

GlobeNewswire March 25, 2019

OpGen Reports Fourth Quarter and 2018 Financial Results and Provides Business Update

GlobeNewswire February 26, 2019

OpGen Appoints R. Don Elsey to Board of Directors

GlobeNewswire February 25, 2019

OpGen Completes Clinical Trials for its Initial FDA 510(k) Submission

GlobeNewswire February 5, 2019

OpGen Completes CDC Contract to Develop Clinical Support Mobile-Based Tools for Antimicrobial Stewardship and Infection Control

GlobeNewswire December 18, 2018

OpGen Receives Regulatory Approval to Market Pathogen Identification Products in Colombia

GlobeNewswire December 4, 2018

Detailed Research: Economic Perspectives on OpGen, Viavi Solutions, Domo, LM Funding America, Orion Energy, and Rimini Street — What Drives Growth in Today's Competitive Landscape

GlobeNewswire November 21, 2018